

A Behavioral Assay to Examine the Effects of Kavalactones on *Caenorhabditis elegans* Neuromuscular Excitability

Bwarenaba B. Kautu^{1, *, #, \$a}, Jessie Chappel^{1, #}, Kellie Steele¹, Juliana Phillips¹
and M. Shawn Mengarelli^{1, \$b}

¹Biology Department, Greenville University, Greenville, IL, USA; ^{\$a}Present address: Harvard Medical School, Boston, MA, 02115, USA; ^{\$b}Present address: A.T. Still University of Health Sciences, Kirksville College of Osteopathic Medicine, Kirksville, MO, USA

*For correspondence: bwarenaba_kautu@hms.harvard.edu or bwarenaba.kautu@greenville.edu

#Contributed equally to this work

[Abstract] Kavalactones are a class of lactone compounds found in Kava, a traditional beverage from the South Pacific Islands that is derived from the root of *Piper methysticum*. When consumed, these compounds produce sedative and anxiolytic effects, suggesting their potent actions on the nervous system. Here, we provide a protocol to examine the effects of kavalactones on *C. elegans* neuromuscular excitability. Our methodology could provide insight into the neurophysiological actions of kavalactones.

Keywords: Kava, Kavalactones, Lactone, *C. elegans*, Neuromuscular, Pacific, Beverage

[Background] Kava, a tranquilizing beverage from the Pacific Islands, has been consumed by Pacific Islanders for centuries (Rowe *et al.*, 2011; Kautu *et al.*, 2017). Kava contains a group of lipophilic compounds called kavalactones, which are believed to be responsible for the sedative, anxiolytic, and other therapeutic effects of the drink (Rowe *et al.*, 2011; Savage *et al.*, 2015; Kautu *et al.*, 2017). Here, we provide a protocol to examine the effects of kavalactones on neuromuscular activity, using *C. elegans* as a model system (Kautu *et al.*, 2017). In our assay, we showed that administration of aqueous kavalactone solution induced epileptic-like convulsions and paralysis in a dose-responsive manner. These manifestations are suggestive of the modulatory actions of kavalactones on the neuromuscular junction. Thus, our protocol could provide important insight into the neurophysiological actions of kavalactones.

Materials and Reagents

1. Petri dishes, sterile (Carolina Biological Supply, catalog number: 741248)
2. 2 ml centrifuge tubes (Thomas Scientific, catalog number: 111572LK)
3. P1000 pipette tips, sterile (Carolina Biological Supply, catalog number: 215060)
4. P200 pipette tips, sterile (Carolina Biological Supply, catalog number: 215050)
5. 0.5 L bottle
6. *E. coli* OP50 (Carolina Biological Supply, catalog number: 155073)
7. *C. elegans* N2 (wild-type)
8. Kava pills (Gaia Herbs, catalog number: 90A10060)
9. NaCl (Sigma-Aldrich, CAS: 7647-14-15)
10. Peptone (Sigma-Aldrich, catalog number: 70176-100G)
11. Difco Bacto agar (Carolina Biological Supply, catalog number: 156783B)
12. CaCl₂ dihydrate (Fisher Scientific, catalog number: C79 500)
13. MgSO₄ (Sigma-Aldrich, CAS: 7487-88-9)
14. Potassium Phosphate Monobasic (KH₂PO₄) (Sigma-Aldrich, CAS: 7778-77-0)
15. Potassium Phosphate Dibasic (K₂HPO₄) (Sigma-Aldrich, CAS: 7758-11-4)
16. Cholesterol (Fisher Science Education, CAS: 57-88-5)
17. Hypochlorite solution (Sigma-Aldrich, CAS: 7681-52-9)
18. NaOH (Sigma-Aldrich, CAS: 1310-73-2)
19. 95% ethanol (Sigma-Aldrich, CAS: 64-47-5)
20. 1 M CaCl₂ stock solution (see Recipes)
21. 1 M MgSO₄ stock solution (see Recipes)
22. 1 M Potassium Phosphate stock solution (pH 6) (see Recipes)
23. 5 mg/ml Cholesterol stock (see Recipes)
24. Nematode Growth Medium (NGM) Agar plates (see Recipes)
25. Bleach sodium hypochlorite solution (see Recipes)
26. Kava stock solution (5 mg/ml) (see Recipes)

Equipment

1. P200 and P1000 micropipette
2. Sharp Edged Scissors
3. Autoclave
4. Bench-top Micro Centrifuge (Oxford Lab Products, model: C12V)
5. Meiji EMT Stereomicroscope on PBH Stand (Meiji Techno, models: EMT-1, PBH Stand, MA502)
6. Microscope Digital Camera (OMAX Microscope, catalog number: A3550UPA-R75)
7. Platinum wire worm pick (Genesee Scientific, catalog number: 59-AWP)
8. Sterile incubator

Software

1. OMAX ToupView 3.7
2. Microsoft Office 2010 Excel (Microsoft Corporation, Redmond, USA)

Procedure

A. Synchronization of *C. elegans* via sodium hypochlorite treatment

1. First, allow gravid adult N2 (wild-type) worms to grow at 20 °C and lay embryos on NGM plates seeded with *E. coli* OP50 strain (Brenner, 1974). Once there is a sufficient number of embryos to be used for the assays, the worm stages should be collected, washed, and synchronized. To collect worms, use a P1000 micropipette to dispense 1,000 µl of DI water onto the plate to pool the worms and embryos into one spot. Pipette the water containing the worms into a 2 ml microcentrifuge tube and centrifuge at room temperature for 1 min at 7,558 x g. Carefully pipette off the excess liquid without disturbing the worm pellet.

Note: To avoid strain loss, a few worms should be transferred to a seeded NGM plate prior to collection and synchronization; all worms from this point on will be used in the assay.

2. Prior to synchronizing the worms, dilute 20% stock of bleach sodium hypochlorite solution to 10-15% using distilled water. Synchronize the worms by incubating them in the diluted bleach sodium hypochlorite solution (10-15%) for 3-5 min.
3. Centrifuge the tube at room temperature for 30 sec at 7,558 x g. Carefully remove excess bleach sodium hypochlorite solution by pipetting. Resuspend the pellet using 500 µl of DI water. Centrifuge at room temperature for another minute at 7,558 x g. Remove excess DI water, leaving the pellet intact.

Note: Do not incubate the worms for more than 5 min, including time in the centrifuge. Also, we found that carryover bacteria does not interfere with the assay. However, an excessive amount of carryover bacteria must be avoided. An experimenter can do this by controlling the amount of bacteria that is initially seeded on the plate. In general, we seed 100 x 200 mm NGM plates with 150-200 µl of OP50 bacteria.

4. Collect the embryos and the dead worms from the microcentrifuge tube using a P200 or P1000 micropipette and transfer them to a new NGM plate seeded with OP50 bacteria. It is best to transfer the dead worms and the embryos to the edge of the seeded plate not covered with OP50 bacteria.
5. Allow the embryos to hatch and grow until the L4 to young adult, stage. This will take approximately two days.

B. Treatment of worms with aqueous kavalactone solutions

1. Transfer L4 to young adult worms to 2 ml microcentrifuge tubes. This can be done using the same method of washing and collecting described previously.

2. Prepare 0 mg/ml, 0.2 mg/ml, 0.4 mg/ml, 0.6 mg/ml, 0.8 mg/ml and 1.0 mg/ml kavalactone solutions by diluting the stock solution (5 mg/ml) with distilled water.
3. Suspend worms in 500 μ l of the prepared kavalactone concentrations (above).
Note: Our kavalactone solution was made using a kavalactone supplement purchased from Gaia Herbs, Inc. (Brevard, NC, USA). Stocks of kavalactone solutions can be stored for up to 2 months at 4 °C. It is important to shake and mix the kavalactone solution well before using it.
4. Incubate the worms in the pre-warmed kavalactone solution (in the 2 ml microcentrifuge tubes) for 30 min at room temperature. During incubation gently invert the tubes 5-8 times. Do this 5 times during the 30-min time span.
5. Following the 30-min incubation, centrifuge the tubes at room temperature for 2 min at approximately 7,558 x g.
6. Remove excess solution, while leaving the pellet of worms intact.
7. Rinse the worms with 200 μ l of distilled water, resuspending the pellet, and centrifuge again at room temperature for an additional 2 min at 7,558 x g.
8. Remove the excess liquid, leaving a sufficient amount to transfer the worms. Using a P200 or P1000 micropipette, transfer approximately 40 worms from the kavalactone solution to new, dry 60 mm NGM plates without *E. coli* bacteria.
Note: Worms can be lost during the resuspension/transfer process, so it's a good idea to start with a higher number of worms than necessary for the assay to account for loss.

C. Scoring worms for convulsions and paralysis

1. Use a dissecting/stereo microscope to count the worms as they are being transferred to the clean 60 mm NGM plate.
2. Allow the worms to acclimate to the new environment for 15 min before scoring. Here, the experimenter can spread out the worms using a worm pick to prevent them from clumping together in one spot.
3. When scoring, observe the worms for convulsions and paralysis. The convulsions manifest as full body repetitive muscle contractions and paralysis. Paralysis is characterized as no visible movement upon observation. Since many convulsing worms progressively become paralyzed over the course of time, we treated convulsions and paralysis as one variable in this particular assay (see Figure 1).




Figure 1. A dose-response curve of kavalactone-induced convulsions and paralysis in *C. elegans* N2 (wild-type) worms. Three independent experiments were performed at each concentration and the response levels of the worms were averaged and converted to percent. For each experiment (at each concentration) 40 worms were scored (n = 120). At 0 mg/ml, *C. elegans* worms were dissolved in DI water without kavalactones (negative control). All error bars indicate standard deviations (SD) for the 3 averaged experiments.

- Record movies of convulsing and paralyzed worms after kavalactone treatment for a minimum of 30 sec, using a suitable video camera or device. Next, observe and quantify the number (percentage) of worms exhibiting any of the following responses: anterior-posterior full body convulsions (Video1), progression from anterior-posterior full body convulsions to full body paralysis (Video 2), and full body paralysis (Video 3):



Video 1. A wild-type N2 worm exhibiting strong full body convulsions (repetitive anterior-posterior muscle contractions) when treated with 1 mg/ml kavalactone aqueous solution



Video 2. A wild-type N2 worm showing progression from convulsion to full body paralysis when exposed to 1 mg/ml kavalactone aqueous solution



Video 3. A wild-type N2 worm showing full body paralysis when treated with 1 mg/ml kavalactone aqueous solution

Data analysis

We calculated percent averages and standard deviations for all experiments using Microsoft Office 2010 Excel (Microsoft Corporation, Redmond, USA).

Notes

This protocol can be adapted for other *C. elegans* mutants of interest.

Recipes

1. 1 M CaCl_2 stock solution
Dissolve 7.35 g of CaCl_2 in 50 ml of DI H_2O

- Autoclave for 30 min at 121 °C
Store at room temperature
2. 1 M MgSO₄ stock solution
Dissolve 6.02 g of MgSO₄ in 50 ml of DI H₂O
Autoclave for 30 min at 121 °C
Store at room temperature
 3. 1 M Potassium Phosphate (pH 6) stock solution
Dissolve 35.6 g of K₂HPO₄ and 108.3 g of KH₂PO₄ in 1 L of DI water
Autoclave for 30 min at 121 °C
Store at room temperature
 4. 5 mg/ml Cholesterol stock
Add 250 mg of cholesterol to 50 ml 95% ethanol
Mix on a rotator until fully dissolved
Store the cholesterol solution at room temperature
 5. Nematode Growth Medium (NGM) Agar plates-recipes
Add 1.2 g of NaCl, 1.0 g of peptone, and 6.8 g of Difco Bacto agar to 400 ml of DI H₂O in a 0.5-L bottle
Autoclave for 25 min at 121 °C
Allow media to cool to approximately 55-60 °C, then add 400 µl of 1 M CaCl₂, 400 µl of 1 M MgSO₄, 10 ml of potassium phosphate (pH 6), and 400 µl of 5 mg/ml cholesterol
Mix gently after adding each component
Store plates in a sterile 20 °C incubator
 6. Bleach sodium hypochlorite solution
Combine 8.25 ml of DI H₂O, 3.75 ml of 1 M NaOH, and 3.0 ml of sodium hypochlorite
Store at room temperature
 7. Kava stock solution (5 mg/ml)
Dissolve 1 kava pill in 15 ml of DI H₂O
Store at 4 °C
The pill (caplet) can be cut open with scissors

Acknowledgments

This study was supported by the Biology Department and the Catalyst Fund of the Math and Science Division of Greenville University. This protocol was adapted and modified from a previous study published in 2017 (Kautu *et al.*, 2017).

Competing interests

The authors declared no competing or conflicts of interests.

References

1. Brenner, S. (1974). [The genetics of *Caenorhabditis elegans*](#). *Genetics* 77(1): 71-94.
2. Kautu, B. B., Phillips, J., Steele, K., Mengarelli, M. S. and Nord, E. A. (2017). [A behavioral survey of the effects of kavalactones on *Caenorhabditis elegans* neuromuscular transmission](#). *J Exp Neurosci* 11: 1179069517705384.
3. Rowe, A., Zhang, L. Y. and Ramzan, I. (2011). [Toxicokinetics of kava](#). *Adv Pharmacol Sci* 2011: 326724.
4. Savage, K. M., Stough, C. K., Byrne, G. J., Scholey, A., Bousman, C., Murphy, J., Macdonald, P., Suo, C., Hughes, M., Thomas, S., Teschke, R., Xing, C. and Sarris, J. (2015). [Kava for the treatment of generalised anxiety disorder \(K-GAD\): study protocol for a randomised controlled trial](#). *Trials* 16: 493.